← Search & browse all drugs
GENITO URINARY SYSTEM AND SEX HORMONES › OTHER GYNECOLOGICALS › OTHER GYNECOLOGICALS › Prolactine inhibitors
terguride
G02CB06
Forms & Strengths
- Oral tablets: 0.25 mg
- Oral tablets: 0.5 mg
Adult Dosing
- Hyperprolactinemia: 0.25 mg to 0.5 mg orally once or twice daily
- Parkinson's disease (adjunct/monotherapy): Titrated gradually from 0.25 mg daily up to 2-4 mg daily in divided doses
Pediatric Dosing
- Safety and efficacy in pediatric patients not established
Indications
- Hyperprolactinemia and related disorders
- Inhibition of lactation
- Parkinson's disease
Mechanism of Action
- Dopamine receptor agonist (partial agonist at D2 receptors)
- Serotonin receptor antagonist (specifically 5-HT2A and 5-HT2B)
- Suppresses pituitary prolactin secretion and stimulates dopaminergic pathways in the CNS
Contraindications
- Hypersensitivity to terguride or ergot alkaloids
- Uncontrolled hypertension
- Severe cardiovascular disease
- History of valvular heart disease or fibrotic disorders
Adverse Reactions
- Nausea, vomiting, dyspepsia
- Orthostatic hypotension, dizziness
- Headache, fatigue, somnolence
- Psychiatric disturbances (hallucinations, confusion in high doses)
Drug Interactions
- Dopamine antagonists (antipsychotics, metoclopramide) may antagonize therapeutic effects
- Antihypertensive agents may produce additive hypotensive effects
- Strong CYP3A4 inhibitors may increase plasma concentrations of ergot derivatives
Curated Content: Needs Vetting Before Put to Clinical Use